The latest biotech news

News and Trends 16 Feb 2016

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

I mean, Clinical depression is a tough indication for Biotech to tackle – particularly when facing off a ’55-year old’ generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer in its pipeline, despite this phase IIb failure in Glasgow. The trial’s aims were to determine whether ETS6103 was an antidepressant capable of treating the patients for […]

February 16, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 16 Feb 2016

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a rare blood disease. Now the New England Journal of Medicine has published their phase II results. Ablynx often makes our biotech headlines, be it with the curious science of their nanobody platform or with their partnerships with […]

February 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Feb 2016

The Only Real European Biotech Unicorns in 2016

Unicorns are private fast-growing companies valued more than a billion euro/dollars. This club is getting bigger and bigger, 146 companies while I’m writing this article (look at the full list on the Wall Street Journal). There is a very reduced number of Biotech unicorns worldwide and even less in Europe. There are actually only 3: […]

February 16, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 15 Feb 2016

Europe’s Richest Microbiome Biotech Acquires Irish Start-up To Accelerate!

Have you ever heard of 4D pharma (UK)? Well, it’s become one of the biggest and cash-rich players in the European Microbiome scene. Perhaps the acquisition of this Irish Chronic disease spin-off will bring their name to the spotlight… 4D pharma in Leeds (England) acquired Tucana, a spin-off from the University College Cork (UCC), to complement its therapeutic platform […]

February 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 15 Feb 2016

‘Every Droplet Counts’ with €1M Investment into French Microfluidic Start-Up

MilliDrop (France) designs and develops cell culture machines based on millifluidic technology for bacterial research and diagnostics, and has now secured a €1M fund-raising from Seventure. Millidrop will use the fund to start producing trial runs of its first machine, the MilliDrop Analyzer. This machine uses millifluidics technology to culture and analyse micro-organisms. The company is also under the Pierre-Gilles […]

February 15, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 15 Feb 2016

Why Text Mining will Revolutionize Big Data in Biotech

Currently, searching information within ‘big data’ is performed via key-words, often resulting in a high number of results that are not always relevant to your initial question. Now, imagine a tool that gives a more precise answer to your question with the same ease of use. That’s the power of text and data mining, and it’s […]

February 15, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 15 Feb 2016

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

AiCuris is a Biotech company based on the Bayer Life Sciences park in Wuppertal (Germany). It is working on new anti-infective drugs and is a former spin-off of Germany’s biggest Pharma Company. It’s celebrating its 10th birthday this year, which is good reason to interview the CEO… So AiCuris is working on anti-infective drugs for […]

February 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 13 Feb 2016

What happened this week? 8 great innovators, PD-L1 combo, Genzyme

Monday: Here are 8 of Forbes’ Under 30 Year Olds Transforming European Biotech Tuesday: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type Wednesday: What’s the situation in France two weeks after the Trial Failure? Thursday: Why is Genzyme still Crazy Successful 5 Years after Sanofi’s Acquisition? Friday: World’s Largest Genome Sequencing Project partners […]

February 13, 2016 - 1 minutemin - By Philip Hemme

News and Trends 12 Feb 2016

World’s Largest Genome Sequencing Project partners with Global Leader in NGS

Genomics England (UK) today announce a partnership with the Next-Generation Sequencing Giant, Illumina (US), to develop a platform that can be used to improve and automate genome interpretation as part of the 100,000 Genome Project. The tools will operate within the Genomics England secure database to enable researchers and clinicians to access information and reports more readily. […]

February 12, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 12 Feb 2016

Biotech of the week: Nordic Nanovector & its ARC technology

This week we say ‘au revoir’ to Nantes and head back up to the Scandinavian country that is Norway, in particular it’s capital city, Oslo – the location of our biotech of the week, Nordic Nanovector. City: Oslo, Norway Founded: 2009 Employees: +/- 30 (as off 11/15) Financial Data: €156M Market Cap (on 23/11/2015) CEO: Missions: Betalutin, a potential new treatment […]

February 12, 2016 - 1 minutemin - By Philip Hemme

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Feb 2016

“Actelion could be the First European-born Biopharma to make it to the Major League”

This is what the founder & CEO Jean-Paul Clozel of Actelion (Switzerland) said at the announcement of the 2015 financial results for the company. And it’s definitely true. Actelion is the only European born biopharma to have over 1K employees (in fact over 2,547 of them). This is already a big achievement but not their greatest… For example, in 2015, […]

February 10, 2016 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

The Only Real European Biotech Unicorns in 2016

Europe’s Richest Microbiome Biotech Acquires Irish Start-up To Accelerate!

‘Every Droplet Counts’ with €1M Investment into French Microfluidic Start-Up

Why Text Mining will Revolutionize Big Data in Biotech

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

What happened this week? 8 great innovators, PD-L1 combo, Genzyme

World’s Largest Genome Sequencing Project partners with Global Leader in NGS

Biotech of the week: Nordic Nanovector & its ARC technology

Sanofi-Genzyme: Still successful 5 years after the acquisition?

“Actelion could be the First European-born Biopharma to make it to the Major League”

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!